Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Capital Expenditures: 2019-2024

Historic Capital Expenditures for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $9.3 million.

  • Nurix Therapeutics' Capital Expenditures rose 15.51% to $2.7 million in Q3 2025 from the same period last year, while for Aug 2025 it was $11.0 million, marking a year-over-year increase of 12.54%. This contributed to the annual value of $9.3 million for FY2024, which is 10.38% up from last year.
  • As of FY2024, Nurix Therapeutics' Capital Expenditures stood at $9.3 million, which was up 10.38% from $8.4 million recorded in FY2023.
  • In the past 5 years, Nurix Therapeutics' Capital Expenditures registered a high of $12.2 million during FY2022, and its lowest value of $4.6 million during FY2020.
  • For the 3-year period, Nurix Therapeutics' Capital Expenditures averaged around $10.0 million, with its median value being $9.3 million (2024).
  • Per our database at Business Quant, Nurix Therapeutics' Capital Expenditures skyrocketed by 175.77% in 2020 and then plummeted by 31.39% in 2023.
  • Over the past 5 years, Nurix Therapeutics' Capital Expenditures (Yearly) stood at $4.6 million in 2020, then increased by 24.34% to $5.7 million in 2021, then soared by 116.29% to $12.2 million in 2022, then slumped by 31.39% to $8.4 million in 2023, then increased by 10.38% to $9.3 million in 2024.